Compare HLX & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | VIR |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 1996 | 2019 |
| Metric | HLX | VIR |
|---|---|---|
| Price | $8.73 | $9.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.50 | ★ $19.63 |
| AVG Volume (30 Days) | 1.9M | ★ 4.4M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $876,561,000.00 | $68,556,000.00 |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $4.97 | $925.73 |
| P/E Ratio | $41.62 | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $4.16 |
| 52 Week High | $10.75 | $10.91 |
| Indicator | HLX | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 56.24 |
| Support Level | $6.03 | $4.95 |
| Resistance Level | $10.75 | $10.91 |
| Average True Range (ATR) | 0.42 | 0.71 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 4.09 | 25.50 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.